References
- Ayenew Z, Puri V, Kumar L, Bansal AK. 2009. Trends in pharmaceutical taste masking technologies: a patent review. Recent Pat Drug Deliv Formul. 3:26–39.
- Bar-Shalom D, Klaus R. 2014. Pediatric formulations: a roadmap. Berlin, Germany: Springer.
- Boggia R, Turrini F, Villa C, Lacapra C, Zunin P, Parodi B. 2016. Green extraction from pomegranate marcs for the production of functional foods and cosmetics. Pharmaceuticals (Basel). 9:E63.
- Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L. 2013. Clinical guideline: management of gastroparesis. Am J Gastroenterol. 108:18–37.
- Committee for Medicinal Products for Human Use (CHMP). 2013. Reflection paper: Formulation of choice for the paediatric population. https://www.ema.europa.eu/en/formulations-choice-paediatric-population.
- Committee for Medicinal Products for Human Use (CHMP). 2005. Formulations of choice for the peadiatric population. In: EMEA/CHMP/PEG/194810/2005. London: European Medicines Agency https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-formulations-choice-paediatric-population_en.pdf.
- Commitee P. 2013. Guideline on pharmaceutical development of medicines for paediatric use. London: European Medicines Agency. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf.
- El-Enany N. 2008. Second derivative synchronous fluorescence spectroscopy for the simultaneous determination of metoclopramide and pyridoxine in syrup and human plasma. J AOAC Int. 91:542–550.
- Entezariasl M, Khoshbaten M, Isazadehfar K, Akhavanakbari G. 2010. Efficacy of metoclopramide and dexamethasone for postoperative nausea and vomiting: a double-blind clinical trial. East Mediterr Health J. 16:300–303.
- Flank J, Robinson PD, Holdsworth M, Phillips R, Portwine C, Gibson P, Maan C, Stefin N, Sung L, Dupuis LL. 2016. Guideline for the treatment of breakthrough and the prevention of refractory chemotherapy-induced nausea and vomiting in children with cancer. Pediatr Blood Cancer. 63:1144–1151.
- Hanna GM, Lau-cam CA. 1991. 1H-NMR spectroscopic assay method for metoclopramide hydrochloride in tablets and injections. Drug Dev Ind Pharm. 17:975–984.
- Khan A, Naqvi SB, Shoaib MH, Yousaf RI, Khan J, Hanif M, Madni A. 2012. Validation and application of RP-HPLC method for the quantification of metoclopramide hydrochloride in oral formulations prepared for IVIVC studies. Pak J Pharm Sci. 25:135–140.
- Kumar D, Goswami DS, Tomar P, Kaur S. 2014. Formulation and characterization of chewable tablets of paracetamol and metoclopramide hydrochloride. J Appl Pharm Res. 2:10–15.
- Matsui D. 2007. Current issues in pediatric medication adherence. Paediatr Drugs. 9:283–288.
- Mennella JA, Pepino MY, Beauchamp GK. 2003. Modification of bitter taste in children. Dev Psychobiol. 43:120–127.
- Mennella JA, Reed DR, Mathew PS, Roberts KM, Mansfield CJ. 2015. “A spoonful of sugar helps the medicine go down”: bitter masking by sucrose among children and adults. Chem Senses. 40:17–25.
- Mirajkar Remsha Nilesh DMS, Rameshrao KD. 2012. Taste masking methods and agents in pharmaceutical formulations. Int Res J Pharm. 3:67–70.
- Mishriky BM, Habib AS. 2012. Metoclopramide for nausea and vomiting prophylaxis during and after Caesarean delivery: a systematic review and meta-analysis. Br J Anaesth. 108:374–383.
- Mycek JM, Harvey RA, Champe PC, Howland RD. 2006. Lippincott's illustrated reviews: pharmacology. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins.
- Navari RM. 2015. Treatment of breakthrough and refractory chemotherapy-induced nausea and vomiting. Biomed Res Int. 2015:595894.
- Periodic Survey #44 Patient Compliance with Prescription Regimens. 2000. https://www.aap.org/en-us/professional-resources/Research/Pages/PS44_Executive_Summary_PatientCompliancewithPrescriptionRegimens.aspx
- Randale SA, Dabhi CS, Tekade AR, Belgamwar VS, Gattani SG, Surana SJ. 2010. Rapidly disintegrating tablets containing taste masked metoclopramide hydrochloride prepared by extrusion-precipitation method. Chem Pharm Bull. 58:443–448.
- Regulation. EU/872/2012 and EU/873/2012. 2013. Off J Eur Union 2013. https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2012:267:0162:0164:en:PDF.
- Sharma P, McClees SF, Afaq F. 2017. Pomegranate for prevention and treatment of cancer: an update. Molecules 22:177–195.
- Sohi H, Sultana Y, Khar RK. 2004. Taste masking technologies in oral pharmaceuticals: recent developments and approaches. Drug Dev Ind Pharm. 30:429–448.
- Stosik AG, Junginger HE, Kopp S, Midha KK, Shah VP, Stavchansky S, Dressman JB, Barends DM. 2008. Biowaiver monographs for immediate release solid oral dosage forms: metoclopramide hydrochloride. J Pharm Sci. 97:3700–3708.
- Ulu ST. 2012. High performance liquid chromatography for the determination of metoclopramide in pharmaceutical preparations using pre-column derivatization with fluorescamine. Chin J Chem. 30:634–638.
- World Health Organization. 2012. Development of paediatric medicines: points to consider in formulation, annex 5. In: Kopp S, editor. Essential medicines and health products information portal, no. 970 series. Geneva, Switzerland: WHO; p. 199–225.
- Zarfeshany A, Asgary S, Javanmard SH. 2014. Potent health effects of pomegranate. Adv Biomed Res. 3:100.
- Zenita Devi O, Basavaiah KB, Vinay KB, Revanasiddappa HD. 2016. Sensitive spectrophotometric determination of metoclopramide hydrochloride in dosage forms and spiked human urine using vanillin. Arab J Chem. 9:S64–S72.